Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Salmonella Outbreak Triggers Recall of Cucumbers in 26 States
MONDAY, Dec. 2, 2024 -- Sixty-eight people have been sickened and 18 have been hospitalized in a salmonella outbreak linked to whole cucumbers sold in 26...
Switch From Animal to Plant Proteins Greatly Boosts Heart Health
MONDAY, Dec. 2, 2024 -- Moving away from meat to plants as a main source of protein will do wonders for your heart, new research finds.The 30-year study found...
Workers Who Make Kitchen Countertops Face Big Lung Hazards
MONDAY, Dec. 2, 2024 -- The workers who cut and finished your sleek stone countertop may be paying a price in poor lung health, new research shows.Breathing...
When's Best Time for Your COVID Booster? That May Depend on You
MONDAY, Dec. 2, 2024 -- Folks might want to try timing their COVID-19 booster vaccine to coincide with a period of increased transmission in their area, a new...
Antibiotics or Surgery: What's Best for Child Appendicitis?
MONDAY, Dec. 2, 2024 -- For decades, surgery to remove an inflamed appendix has been a rite of childhood for many.But a new study says treating appendicitis...
Monthly News Roundup - November 2024
Bimzelx Indications Expanded to Include Hidradenitis Suppurativa, a Debilitating Skin Condition UCB’s Bimzelx (bimekizumab-bkzx) has been granted a new...
Community-Level Social, Environmental Factors Tied to Mild Cognitive Impairment
WEDNESDAY, Nov. 27, 2024 -- Several community-wide social and environmental factors are associated with the onset of mild cognitive impairment (MCI) in older...
2021 to 2022 Saw Decline in Abortions in the United States
WEDNESDAY, Nov. 27, 2024 -- From 2021 to 2022, there was a decrease in the number of abortions performed, as well as in the abortion rate and ratio, according...
Family History of Mental Illness Tied to Aggression in Those With CTE
WEDNESDAY, Nov. 27, 2024 -- Chronic traumatic encephalopathy (CTE) pathology influences the effect of first-degree family history of mental illness...
American Heart Association, Nov. 16-18
The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, including...
FDA Approves Rapiblyk (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
Vienna, -- November 27th 2024 -- AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration...
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative...
FDA Approves Imkeldi (imatinib) Oral Solution for the Treatment of Certain Forms of Leukemia and Other Cancers
CAMBRIDGE, Mass.-- November 25, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA...
FDA Approves Attruby (acoramidis) to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Patients with ATTR-CM
PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical...
FDA Grants Accelerated Approval to Ziihera (zanidatamab-hrii) for the Treatment of HER2-Positive Biliary Tract Cancer
DUBLIN, Nov. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval...
UCB Receives U.S. FDA Approval for Bimzelx (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate to Severe Hidradenitis Suppurativa
Brussels (Belgium), November 20, 2024 – 07:00 (CET) – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug...
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
PASADENA, Calif.–(BUSINESS WIRE)–Nov. 18, 2024– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug...
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 18, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug...
Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has...
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
12 November 2024 -- AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab...
Newer Epilepsy Medications Used During Pregnancy Do Not Affect Neurological Development in Children
November 27, 2024 -- Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6...
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
TAIPEI CITY, Taiwan, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Lin BioScience (6696. Taiwan OTC), a clinical-stage biopharmaceutical drug development company focused...
Amgen Announces Robust Weight Loss With MariTide in People Living With Obesity or Overweight at 52 Weeks in a Phase 2 Study
THOUSAND OAKS, Calif., Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2...
Cassava Sciences Topline Phase 3 Data for Simufilam Did Not Meet Co-Primary Endpoints
AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage...
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
NEW HAVEN, Conn., Nov. 25, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.